Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial

Int J Cardiol. 2015 Sep 1:194:60-2. doi: 10.1016/j.ijcard.2015.05.085. Epub 2015 May 15.

Affiliations

¹ Department of Cardiovascular, Respiratory, Geriatric, Anesthesiologic and Nephrologic Sciences, Umberto I Hospital, Sapienza University of Rome, Italy. Electronic address: [email protected].
² Department of Cardiovascular, Respiratory, Geriatric, Anesthesiologic and Nephrologic Sciences, Umberto I Hospital, Sapienza University of Rome, Italy.
³ Interinstitutional Multidisciplinary BioBank (BioBIM), Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele Pisana, Rome, Italy.

PMID: 26011265
DOI: 10.1016/j.ijcard.2015.05.085

No abstract available

Keywords: Clopidogrel; Genetics; High on-treatment platelet reactivity; Prasugrel; Stable coronary artery disease; Ticagrelor.

Publication types

Clinical Trial
Letter
Randomized Controlled Trial

MeSH terms

Adenosine / administration & dosage
Adenosine / analogs & derivatives*
Blood Platelets / drug effects
Blood Platelets / physiology
Clopidogrel
Coronary Artery Disease / blood
Coronary Artery Disease / drug therapy
Coronary Artery Disease / surgery
Coronary Artery Disease / therapy*
Cytochrome P-450 CYP2C19 / genetics
Dose-Response Relationship, Drug
Genetic Variation
Genotype
Humans
Percutaneous Coronary Intervention / methods*
Platelet Aggregation Inhibitors / administration & dosage*
Prasugrel Hydrochloride / administration & dosage*
Purinergic P2Y Receptor Antagonists / administration & dosage*
Ticagrelor
Ticlopidine / administration & dosage
Ticlopidine / analogs & derivatives*

Substances

Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Clopidogrel
CYP2C19 protein, human
Cytochrome P-450 CYP2C19
Prasugrel Hydrochloride
Ticagrelor
Adenosine
Ticlopidine

Associated data

ClinicalTrials.gov/NCT01543932